Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOTOX in pediatric neurogenic detrusor overactivity
NCT01852045Phase 3Completed
- Sponsor
- Allergan
- Start
- Jul 2013
- Primary completion
- Oct 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
A Phase 3 trial of onabotulinumtoxinA in neurogenic detrusor overactivity (NDO), sponsored by Allergan. Started Jul 2013; status: completed.
02
Drugs
onabotulinumtoxinA
03
Conditions
neurogenic detrusor overactivity (NDO)
Beyond the preview
Go deeper on NCT01852045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01852045.